Drug intelligence / Profile preview

LentiGuard

Development stage: Unknown
Lead developer: GlycaNova
Administration: Oral

Overview

LentiGuard is a beta-glucan-based feed ingredient developed by GlycaNova AS, derived from the mycelium of the mushroom *Lentinula edodes* (Shiitake). It is designed for oral administration in animal health, particularly for fish (aquaculture) and livestock. The product acts as an immunomodulator, enhancing the host's innate immune system and host defense mechanisms. By stimulating immune-related responses, it provides anti-infective and potentially anti-tumour effects, helping animals resist pathogens and maintain overall health. It is produced using a proprietary fermentation process that yields high-purity, bioactive (1,3)(1,6)-beta-D-glucans.

Brand names: LentiGuard
Other names: Lentinula edodes mycelium beta-glucanShiitake mycelium beta-glucan

Targets

CLEC7A (Dectin-1)αMβ2 (Integrin αMβ2)

Beyond the preview

Go deeper on LentiGuard.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LentiGuard.

Explore the full profile